Marco Timmers

Marco has cultivated a career spanning over 25 years in pharmaceutical R&D and has held various leadership positions at international biotechnology and pharmaceutical corporations. Before joining Sapreme, he was CEO of Byondis (formerly Synthon Biopharmaceuticals), a clinical-stage biopharmaceutical company developing Antibody-Drug Conjugates (ADCs) targeting intractable cancers and auto-immune diseases. During his time at Byondis, Marco also served as Chief Scientific Officer, guiding the company’s clinical strategies and growth. Before that, he held various positions of increasing responsibility at Organon, Schering-Plough and MSD, such as Head of Medicinal Chemistry, Proof-of-Concept Team Leader and Site Lead Women’s Health and Endocrinology. He holds a MSc and a PhD in bio-organic chemistry from Leiden University in The Netherlands.